A Phase 1 interventional study of AD-118, AD-1181 and AD-118, AD-1181 in Chronic Heart Failure, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Heart Failure with a site in Korea, Republic of — 48 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.
Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 86th largest by planned enrollment of the 109 interventional ones that give a count, is one of 18 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 8 of the 53 other live ones, and was the 142nd registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →48 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
Oslo University Hospital · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 29 more countries
Ages 18+
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 19+
Kyungsub Song · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 16 · Phase 3 40 · Phase 4 15
First in 1983; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 74 is close to the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 227 across the 109 interventional studies, 815 across the 39 observational. Of the 73 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 148 have an industry lead sponsor. The 10 most frequent:
This study is registered under Addpharma Inc., one of the names counted as Yuhan Corporation. Under that name alone:
Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
Yuhan Corporation has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
13 of the studies in Heart Failure with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT07111585Gachon University Gil Medical CenterPersonalized Health Coaching for Patients With HF | 2026-12 |
| NCT06122779Bristol-Myers SquibbStudy to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | 2026-12-14 |
| NCT07379840BayerA Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 148 studies in Heart Failure with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 : Reference drug(AD-1181), Period 2 : Test drug(AD-118) Single-dose oral administration of AD-1181 in Period 1, followed by single-dose oral administration of AD-118 in Period 2.
Drug: AD-118, AD-1181
Period 1 : Test drug(AD-118), Period 2 : Reference drug(AD-1181) Single-dose oral administration of AD-118 in Period 1, followed by single-dose oral administration of AD-1181 in Period 2.
Drug: AD-118, AD-1181
Single-dose oral administration of AD-118, according to randomized treatment sequence in a 2-period crossover design.
Single-dose oral administration of AD-1181, according to randomized treatment sequence in a 2-period crossover design.
Area under the plasma concentration-time curve during dosing interval (AUCt)
AUCt of AD-118
Time frame: [Time Frame: pre-dose (0hour) to 36hours]
Maximum concentration of drug in plasma (Cmax)
Cmax of AD-118
Time frame: Time Frame: pre-dose (0hour) to 36hours]
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Aug 2026, 1 month later.
Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 1 month is below that.
Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.